MERCK & CO, INC. for MERCK & CO INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 21, 2025 | $1,730,000 | Replaced |
| 4th Quarter - Amendment | Apr 21, 2025 | $1,800,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ADAM HUFTALEN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Medicare/Medicaid MMM
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid VBPs for Patients (MVP) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2024 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP); Medicare coverage of COVID antiviral medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ADAM HUFTALEN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Taxation/Internal Revenue Code TAX
Issues relating to, Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HUFTALEN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.